Ibrutinib/Rituximab Yields Prolonged PFS in Waldenström Macroglobulinemia

11:57 EDT 4 Jun 2018 | Cancer Networks

Jun 4, 2018

In the randomized phase III iNNOVATE trial, adding ibrutinib to rituximab significantly improved PFS in patients with Waldenström macroglobulinemia.

More From BioPortfolio on "Ibrutinib/Rituximab Yields Prolonged PFS in Waldenström Macroglobulinemia"